This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

12 Dec 2016

Lonza confirms interest in Capsugel

Acquisition would "fit perfectly with Lonza's Healthcare Continuum strategy".

Last week, Lonza announced its agreement to divest its peptides business and operations in Braine-l’Alleud, Belgium, to PolyPeptide, to allow it to fully focus on its other technologies. Already, the company has its eye on Capsugel, which designs, develops and manufactures a wide range of innovative dosage forms for the biopharmaceutical and consumer health and nutrition industries.

In light of recent press speculations that Lonza is in final negotiations with KKR regarding the potential acquisition of Capsugel, Lonza has confirmed that it has expressed a strong interest in this successful company as it would fit perfectly with Lonza’s Healthcare Continuum strategy and strengthen its position as leading supplier to a number of important healthcare markets. A successful acquisition would be value adding and be within Lonza’s stated acquisition criteria.

Lonza emphasizes that there can be no certainty as to the outcome of the discussions or whether an acquisition will be completed.

Related News